USANA Health Sciences, Inc. (NYSE:USNA – Get Free Report) CEO Jim Brown sold 5,000 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $29.47, for a total transaction of $147,350.00. Following the completion of the transaction, the chief executive officer now directly owns 15,716 shares of the company’s stock, valued at approximately $463,150.52. The trade was a 24.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
USANA Health Sciences Price Performance
Shares of USNA opened at $30.86 on Thursday. The business’s fifty day moving average price is $33.20 and its 200 day moving average price is $36.34. USANA Health Sciences, Inc. has a 12-month low of $27.71 and a 12-month high of $50.32. The stock has a market capitalization of $588.10 million, a PE ratio of 10.90, a price-to-earnings-growth ratio of 0.93 and a beta of 0.98.
USANA Health Sciences (NYSE:USNA – Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.49 by $0.15. The company had revenue of $213.61 million during the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. As a group, research analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.
Institutional Investors Weigh In On USANA Health Sciences
Wall Street Analysts Forecast Growth
USNA has been the subject of several research analyst reports. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. DA Davidson reduced their price target on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, February 27th. Finally, Sidoti cut shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th.
Check Out Our Latest Analysis on USANA Health Sciences
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Featured Stories
- Five stocks we like better than USANA Health Sciences
- What is the Australian Securities Exchange (ASX)
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- Why Are Stock Sectors Important to Successful Investing?
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- Short Selling – The Pros and Cons
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.